WO2002008203A3 - 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4 - Google Patents
3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4 Download PDFInfo
- Publication number
- WO2002008203A3 WO2002008203A3 PCT/US2001/023097 US0123097W WO0208203A3 WO 2002008203 A3 WO2002008203 A3 WO 2002008203A3 US 0123097 W US0123097 W US 0123097W WO 0208203 A3 WO0208203 A3 WO 0208203A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vla
- heteroaryl
- leukocyte adhesion
- inhibitors
- adhesion mediated
- Prior art date
Links
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical class C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 title 1
- 235000004279 alanine Nutrition 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001277960A AU2001277960A1 (en) | 2000-07-21 | 2001-07-20 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22013100P | 2000-07-21 | 2000-07-21 | |
US60/220,131 | 2000-07-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002008203A2 WO2002008203A2 (en) | 2002-01-31 |
WO2002008203A3 true WO2002008203A3 (en) | 2002-05-23 |
Family
ID=22822196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/023097 WO2002008203A2 (en) | 2000-07-21 | 2001-07-20 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4 |
Country Status (3)
Country | Link |
---|---|
US (3) | US6794506B2 (en) |
AU (1) | AU2001277960A1 (en) |
WO (1) | WO2002008203A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479492B1 (en) * | 1999-01-22 | 2002-11-12 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
MY162179A (en) * | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
WO2005111020A2 (en) * | 2004-04-30 | 2005-11-24 | Elan Pharmaceuticals, Inc. | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4 |
BRPI0616643A2 (en) | 2005-09-29 | 2011-06-28 | Elan Pharm Inc | carbamate compounds that inhibit vla-4 mediated leukocyte adhesion |
AU2006297220B8 (en) * | 2005-09-29 | 2013-01-31 | Elan Pharmaceuticals, Inc. | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
EP1996559A1 (en) * | 2006-02-27 | 2008-12-03 | Elan Pharmaceuticals Inc. | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4 |
MX2011011326A (en) * | 2009-04-27 | 2012-02-13 | Elan Pharm Inc | Pyridinone antagonists of alpha-4 integrins. |
US20120258093A1 (en) | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
BR112018075992A2 (en) | 2016-06-13 | 2019-04-02 | Cancer Research Tech Ltd | pyridines substituted as dnmt1 inhibitors |
US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3045931A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
JP7214882B2 (en) | 2018-10-30 | 2023-01-30 | ギリアード サイエンシーズ, インコーポレイテッド | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
CN112969687A (en) | 2018-10-30 | 2021-06-15 | 吉利德科学公司 | Quinoline derivatives as alpha 4 beta 7 integrin inhibitors |
WO2020106750A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
KR20220047323A (en) | 2019-08-14 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Compounds for Inhibiting Alpha 4 Beta 7 Integrin |
CN115666704A (en) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract |
EP4284947A1 (en) | 2021-01-29 | 2023-12-06 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4414215A (en) * | 1981-08-24 | 1983-11-08 | Merck & Co., Inc. | N-Acyl derivatives of 6-alkylamino 5-chloro-3-nitropyrazinamines for radiation therapy |
EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
DE69530392D1 (en) | 1994-07-11 | 2003-05-22 | Athena Neurosciences Inc | INHIBITORS OF LEUKOCYTE ADHESION |
US6410729B1 (en) * | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
FR2766183B1 (en) * | 1997-07-17 | 1999-08-27 | Rhone Poulenc Rorer Sa | MEDICINES CONTAINING NEW POLYHYDROXYBUTYLPYRAZINES, NEW POLYHYDROXYBUTYLPYRAZINES AND THEIR PREPARATION |
US6011038A (en) * | 1997-09-05 | 2000-01-04 | Merck & Co., Inc. | Pyrazinone thrombin inhibitors |
US20020169101A1 (en) * | 1999-05-10 | 2002-11-14 | Gonzalez Maria Isabel | Treatment of sexual dysfunction |
ATE384704T1 (en) * | 1999-12-17 | 2008-02-15 | Novartis Vaccines & Diagnostic | PYRAZINE-BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 |
DE10059864A1 (en) * | 2000-11-30 | 2002-06-13 | Gruenenthal Gmbh | Substituted amino-furan-2-yl-acetic acid and amino-thien-2-yl-acetic acid derivatives |
-
2001
- 2001-07-19 US US09/910,466 patent/US6794506B2/en not_active Expired - Fee Related
- 2001-07-20 AU AU2001277960A patent/AU2001277960A1/en not_active Abandoned
- 2001-07-20 WO PCT/US2001/023097 patent/WO2002008203A2/en active Application Filing
-
2004
- 2004-07-23 US US10/898,576 patent/US7365073B2/en not_active Expired - Fee Related
-
2007
- 2007-10-16 US US11/873,358 patent/US20080182850A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, vol. 60, no. 44, 1964, Columbus, Ohio, US; YU.P.SHVACHKIN: "POTENTIAL ANTIMETABOLITES.VII.SUBSTITUTED N-4-PYRIMIDYL AMINOACIDS AND THEIR DERIV." page 1829F; column 1; XP002186572 * |
CHEMICAL ABSTRACTS, vol. 81, no. 7, 1974, Columbus, Ohio, US; abstract no. 37791g, KUZMENKO,I.I. ET AL.: "SYNTHESIS AND PROP. OF N-(2-CHLORO-6-METHYL-4-PYRIMIDINYL)AMINO ACIDS." page 410; XP002186573 * |
FIZIOL. AKTIV. VESHCHESTVA, vol. 5, 1973, RUSS., pages 101 - 5 * |
ZH. OBSHCH. KHIM., vol. 33, no. 9, 1963, RUSS, pages 2842 - 8 * |
Also Published As
Publication number | Publication date |
---|---|
US6794506B2 (en) | 2004-09-21 |
US20080182850A1 (en) | 2008-07-31 |
AU2001277960A1 (en) | 2002-02-05 |
US7365073B2 (en) | 2008-04-29 |
WO2002008203A2 (en) | 2002-01-31 |
US20040266763A1 (en) | 2004-12-30 |
US20020052375A1 (en) | 2002-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2290745A1 (en) | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 | |
HK1072608A1 (en) | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | |
WO2002008203A3 (en) | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4 | |
MXPA01007335A (en) | Acyl derivatives which treat vla-4 related disorders. | |
WO2000043354A3 (en) | Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 | |
TW200603788A (en) | Multivalent vla-4 antagonists comprising polymer moieties | |
NO20000451L (en) | Compounds that inhibit leukocyte adhesion mediated by VLA-4 | |
NO20000412L (en) | Dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4 | |
WO2003099231A3 (en) | Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins | |
NO20000452L (en) | Sulfonylated dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4 | |
NO20000414L (en) | Benzyl compounds that inhibit leukocyte adhesion mediated by VLA-4 | |
IL190084A0 (en) | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4 | |
MY151045A (en) | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4 | |
WO2000043371A3 (en) | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 | |
ZA200803016B (en) | Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 | |
WO2002008201A3 (en) | Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4 | |
WO2005111020A3 (en) | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4 | |
AU3246600A (en) | Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists | |
WO2000043413A3 (en) | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |